Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy. ASCO 2011. - Gori, S (J Clin Oncol, 2011)
et al.